A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules

一项针对晚期乳腺癌的顺铂(cis-diamminedichloroplatum II)II期临床研究。两种给药方案。

阅读:1

Abstract

Thirty-six (36) women with metastatic breast cancer refractory to conventional therapies were treated with cis-diamminedichloroplatinum II. Two dose schedules were used sequentially. The first 15 patients received platinum at a dose of 15 mg/m2 daily for 5 days at 28-day intervals. No response was noted in this group. Subsequently, 21 patients were treated with a dose of 100-120 mg/m2 at 28-day intervals, but with additional induced diuresis with saline, furosemide, and mannitol. Among 13 patients evaluable for response, 2 partial responses were observed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。